Methylenetetrahydrofolate reductase (MTHFR) variants and fluorouracil-based treatments in colorectal cancer

Author： Etienne-Grimaldi Marie-Christine Francoual Mireille Formento Jean-Louis Milano Géérard

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.8, Iss.11, 2007-11, pp. : 1561-1566

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Methylenetetrahydrofolate Reductase (MTHFR): A Novel Target for Cancer Therapy

Current Pharmaceutical Design, Vol. 14, Iss. 11, 2008-04 ,pp. : 1143-1150

Bentham Science Publishers

Access to resources Recommend Favorite

Variants in the Dihydropyrimidine Dehydrogenase, Methylenetetrahydrofolate Reductase and Thymidylate Synthase Genes Predict Early Toxicity of 5-Fluorouracil in Colorectal Cancer Patients

By Kristensen MH Pedersen PL Melsen GV Ellehauge J Mejer J

The Journal of International Medical Research, Vol. 38, Iss. 3, 2010-06 ,pp. : 870-883

Field House Publishing

Access to resources Recommend Favorite

Role of cyclin polymorphisms in predicting outcome of 5-fluorouracil-based chemotherapy in colorectal cancer: one piece in a complex puzzle

By LaBonte Melissa J Lenz Heinz-Josef

Pharmacogenomics, Vol. 14, Iss. 14, 2013-11 ,pp. : 1671-1674

Future Medicine

Access to resources Recommend Favorite

Biweekly fluorouracil-based regimen in gastric cancer

Inpharma, Vol. 1, Iss. 1426, 2004-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Pharmacogenetics of Colon Cancer and Potential Implications for 5- Fluorouracil-Based Chemotherapy

Current Pharmacogenomics, Vol. 4, Iss. 1, 2006-03 ,pp. : 57-67

Bentham Science Publishers

Access to resources Recommend Favorite